The IL3 Knockout NCI-H1299 Polyclonal Cells consist of a polyclonal population of NCI-H1299 human non-small cell lung cancer (NSCLC) cells engineered through CRISPR/Cas9-mediated disruption of the interleukin-3 (IL3) gene. This product offers a heterogeneous pool of knockout cells, preserving genetic diversity while ensuring targeted loss of IL3 function. The polyclonal format is well-suited for pooled functional studies, avoiding clonal artifacts and providing a robust platform for analyzing gene function in a relevant lung adenocarcinoma background.
NCI-H1299 is a widely used human NSCLC cell line derived from a lymph node metastasis of a male patient with lung adenocarcinoma. It represents an aggressive, metastatic phenotype and is commonly employed to study the molecular mechanisms driving lung cancer progression, including aberrant signaling pathways and tumor-stroma interactions. The cell line retains key characteristics of metastatic disease, making it an appropriate host for investigating genes that may influence tumor cell survival, proliferation, and immune modulation.
IL3 encodes a multifunctional hematopoietic growth factor that exerts its effects by binding to the heterodimeric IL-3 receptor, composed of IL3RA (alpha subunit) and CSF2RB (beta common subunit). Receptor engagement activates JAK2, which phosphorylates and activates STAT5. Additionally, IL3 signaling recruits adaptor proteins Grb2 and SOS, leading to activation of the Ras-mediated MAPK/ERK pathway, and activates PI3K-AKT signaling through direct interaction with the receptor or secondary messengers. Key downstream effectors include ERK, AKT, and Bcl-2 family members such as Bcl-xL, which collectively promote cell cycle progression and inhibit apoptosis. Upstream, IL3 expression is regulated by T cell receptor activation and cytokines like IL-2 and GM-CSF. Although classically associated with hematopoiesis, ectopic IL3 expression in solid tumors may influence cancer cell biology and the tumor microenvironment.
In the context of NCI-H1299 lung adenocarcinoma, targeted IL3 knockout is predicted to disrupt autocrine or paracrine signaling that sustains tumor cell growth and survival. By abrogating JAK2/STAT5 and MAPK/ERK pathway activation, this knockout model likely attenuates STAT5 and ERK phosphorylation and downregulates anti-apoptotic proteins, rendering cells more susceptible to apoptosis. Consequently, the IL3 Knockout NCI-H1299 Polyclonal Cells serve as a powerful tool for elucidating the contributions of hematopoietic cytokines to epithelial lung cancer biology, particularly in the areas of proliferation, survival, and metastatic signaling.
This knockout cell population is applicable to a range of experimental approaches, including western blotting for phospho-JAK2, phospho-STAT5, and phospho-ERK; RT-qPCR and RNA-seq for transcriptomic analysis; and functional assays such as cell proliferation, apoptosis, and cytokine arrays. The model is especially valuable for drug sensitivity screening against JAK2 or PI3K inhibitors, studies of tumor cell?Cimmune cell cytokine cross-talk, and dissection of MAPK signaling in lung adenocarcinoma. For additional information or technical inquiries, please reach out to Ascent Research.
